search
Back to results

Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 2
Locations
Japan
Study Type
Interventional
Intervention
Dapagliflozin
Placebo
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Type 2 diabetes mellitus, Japanese, phase 2, efficacy, safety, dapagliflozin

Eligibility Criteria

18 Years - 79 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Japanese Subjects with type 2 diabetes mellitus.
  • Strictly/relatively treatment naïve Subjects with HbA1c ≥ 7.0% and ≤ 10%, or Subjects treated with single or two (less than half of the approved maximal dose for each) oral anti-hyperglycaemic agent with HbA1c ≤ 8%.
  • Provision of informed consent.

Exclusion Criteria:

  • Having clinically relevant medical history or concurrent disease such as cardiovascular disease, renal disease, retinopathy, hepatic disease and haematological disease.
  • The investigator(s) judged that the Subject should not participate in the study according to screening test or medical history.

Sites / Locations

  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

1

2

3

4

5

Arm Description

1mg dapagliflozin

2.5mg dapagliflozin

5mg dapagliflozin

10mg dapagliflozin

Placebo

Outcomes

Primary Outcome Measures

Adjusted Mean Change in HbA1c Levels
The primary efficacy endpoint is the absolute change in HbA1c from baseline to Week 12 or the last post-baseline measurement prior to Week 12, if no Week 12 assessment is available.

Secondary Outcome Measures

Adjusted Mean Change in Fasting Plasma Glucose
Change in fasting plasma glucose from baseline to Week 12 or the last post-baseline measurement prior to Week 12, if no Week 12 assessment is available.
Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%
Proportion of participants achieving therapeutic glycemic response defined as glycosylated hemoglobin <7%, after 12 weeks of double-blind therapy

Full Information

First Posted
August 31, 2009
Last Updated
August 9, 2013
Sponsor
AstraZeneca
Collaborators
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT00972244
Brief Title
Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients
Official Title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Trial to Evaluate the Efficacy and Safety of Dapagliflozin as Monotherapy in Japanese Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Study Type
Interventional

2. Study Status

Record Verification Date
August 2013
Overall Recruitment Status
Completed
Study Start Date
August 2009 (undefined)
Primary Completion Date
May 2010 (Actual)
Study Completion Date
May 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca
Collaborators
Bristol-Myers Squibb

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to obtain information on efficacy and safety of dapagliflozin in Japanese patients with Type 2 Diabetes. This will be done by comparing the effect of dapagliflozin to placebo when given in oral doses.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Type 2 diabetes mellitus, Japanese, phase 2, efficacy, safety, dapagliflozin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
417 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
1mg dapagliflozin
Arm Title
2
Arm Type
Experimental
Arm Description
2.5mg dapagliflozin
Arm Title
3
Arm Type
Experimental
Arm Description
5mg dapagliflozin
Arm Title
4
Arm Type
Experimental
Arm Description
10mg dapagliflozin
Arm Title
5
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Drug
Intervention Name(s)
Dapagliflozin
Intervention Description
once daily, 12 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
once daily, 12 weeks
Primary Outcome Measure Information:
Title
Adjusted Mean Change in HbA1c Levels
Description
The primary efficacy endpoint is the absolute change in HbA1c from baseline to Week 12 or the last post-baseline measurement prior to Week 12, if no Week 12 assessment is available.
Time Frame
Baseline to Week 12
Secondary Outcome Measure Information:
Title
Adjusted Mean Change in Fasting Plasma Glucose
Description
Change in fasting plasma glucose from baseline to Week 12 or the last post-baseline measurement prior to Week 12, if no Week 12 assessment is available.
Time Frame
Baseline to Week 12
Title
Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%
Description
Proportion of participants achieving therapeutic glycemic response defined as glycosylated hemoglobin <7%, after 12 weeks of double-blind therapy
Time Frame
At Week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Japanese Subjects with type 2 diabetes mellitus. Strictly/relatively treatment naïve Subjects with HbA1c ≥ 7.0% and ≤ 10%, or Subjects treated with single or two (less than half of the approved maximal dose for each) oral anti-hyperglycaemic agent with HbA1c ≤ 8%. Provision of informed consent. Exclusion Criteria: Having clinically relevant medical history or concurrent disease such as cardiovascular disease, renal disease, retinopathy, hepatic disease and haematological disease. The investigator(s) judged that the Subject should not participate in the study according to screening test or medical history.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Parikh Shamik
Organizational Affiliation
AstraZeneca
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
Anjyo
Country
Japan
Facility Name
Research Site
City
Bunkyo-ku
Country
Japan
Facility Name
Research Site
City
Chuo-ku
Country
Japan
Facility Name
Research Site
City
Daito
Country
Japan
Facility Name
Research Site
City
Kamagaya
Country
Japan
Facility Name
Research Site
City
Kashiwara
Country
Japan
Facility Name
Research Site
City
Matsuyama
Country
Japan
Facility Name
Research Site
City
Nagoya
Country
Japan
Facility Name
Research Site
City
Nakano-ku
Country
Japan
Facility Name
Research Site
City
Naka
Country
Japan
Facility Name
Research Site
City
Nerima-ku
Country
Japan
Facility Name
Research Site
City
Okinawa
Country
Japan
Facility Name
Research Site
City
Osaka
Country
Japan
Facility Name
Research Site
City
Sapporo
Country
Japan
Facility Name
Research Site
City
Shibuya-ku
Country
Japan
Facility Name
Research Site
City
Shinjyuku-ku
Country
Japan
Facility Name
Research Site
City
Suita
Country
Japan
Facility Name
Research Site
City
Uji
Country
Japan
Facility Name
Research Site
City
Wakayama
Country
Japan
Facility Name
Research Site
City
Yamato
Country
Japan

12. IPD Sharing Statement

Citations:
PubMed Identifier
26894924
Citation
Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L. The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol. 2016 Jun;29(3):391-400. doi: 10.1007/s40620-016-0261-1. Epub 2016 Feb 19.
Results Reference
derived

Learn more about this trial

Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients

We'll reach out to this number within 24 hrs